Organon & Co. (OGN) Stock Price, Quote & News

Company Profile

Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 551 430 6900

Website: www.organon.com

Address:

30 Hudson Street, Floor 33, Jersey City, United States

johnmchugh Jan. 30 at 4:00 PM

$OGN what is the proposed Sun Pharma purchase price v current debt after Jada disposal?

5 · Reply

BillionerOfKing Jan. 29 at 8:39 PM

$OGN Current Stock Price: $8.52 Contracts to trade: $10 OGN Feb 20 2026 Call Entry: $0.30 Exit: $0.39 ROI: 29% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

ZacksResearch Jan. 29 at 6:59 PM

$OGN just unlocked up to $465M 💰 — and it’s all about strengthening the core. The company completed the JADA System divestiture to Laborie Medical, bolstering its balance sheet and backing debt reduction to fund women’s health growth. See how this reshapes the company’s financial flexibility 👉 https://www.zacks.com/stock/news/2825616/organon-completes-divesture-of-jada-system-to-laborie-medical?cid=sm-stocktwits-2-2825616-teaser-31084&ADID=SYND_STOCKTWITS_TWEET_2_2825616_TEASER_31084

0 · Reply

ZacksResearch Jan. 29 at 5:59 PM

$OGN divests JADA System for up to $465M — what’s the impact on growth? 🤔 💰 Net proceeds to reduce debt, boosting financial flexibility for women’s health biopharma expansion. 📉 Yet, OGN shares have dipped 11.5% over the past six months while the industry has grown 12.6%. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2825616/organon-completes-divesture-of-jada-system-to-laborie-medical?cid=sm-stocktwits-2-2825616-body-31085&ADID=SYND_STOCKTWITS_TWEET_2_2825616_BODY_31085

0 · Reply

handmedown1 Jan. 27 at 8:22 PM

$OGN i am sure any MMs short are going to try whatever they can to cover lower

0 · Reply

MrNotSoNice Jan. 27 at 5:54 PM

$OGN Long and will add below $7 if it gets there. This stock is stupid cheap and will have its day eventually. 🧐💰📈💊

0 · Reply

PKinUK16 Jan. 25 at 9:31 PM

$ESPR adding to the ridiculousness of it all - check this out: $OGN stock is UP 20% since being chosen to re-sell OUR PRODUCT (BA) in Europe. Meanwhile we are DOWN 19% since the same announcement 😂 even though we benefit immensely from more sales growth. The 20% royalties revert back to us faster and up to $300 million in additional milestones are potentially unlocked in 26 & 27 One stock up 20% and one down 19% on the same fucking news. Make it make sense. You cannot. It’s manipulative bullshit to discourage us and shake retail out. Not falling for it. Fuck you MMs…pay me and all the ESPR holders here

1 · Reply

c0ffee Jan. 24 at 9:43 PM

$OGN asked AI for summary on how attractive this company would be for larger foreign competitors. - USD Currency Devaluation: Effectively lowers the "sticker price" of the acquisition and future cost of debt repayment - Low Valuation: Buyer acquires $6B+ in revenue at a massive discount to peers. - Debt Refinancing: A large buyer can "fix" Organon's balance sheet more efficiently than Organon can - Global Reach: Organon's 140-country distribution network provides instant global scale

0 · Reply

Value1996 Jan. 23 at 3:40 PM

Organon

0 · Reply

BOBJOSCAUWBERGH Jan. 21 at 9:04 PM

$OGN really curious to see if a deal actually gets made. at 14b sale would be around 20/share

0 · Reply

Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026

Jan 28, 2026, 12:45 PM EST - 6 days ago

Organon Completes Divestiture of JADA® System to Laborie

Jan 20, 2026, 10:31 AM EST - 14 days ago

Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report

Jan 16, 2026, 9:12 PM EST - 17 days ago

Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque

Jan 8, 2026, 1:30 AM EST - 26 days ago

Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway

Dec 3, 2025, 12:23 PM EST - 2 months ago

Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Nov 25, 2025, 7:30 AM EST - 2 months ago

Organon To Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 17, 2025, 5:30 AM EST - 2 months ago

Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

Nov 11, 2025, 12:58 PM EST - 3 months ago

Organon: Q3 Earnings Lift Struggling Stock - But Not For Long, I Suspect

Nov 11, 2025, 11:40 AM EST - 3 months ago

Organon Analysts Cut Their Forecasts Following Q3 Results

Nov 10, 2025, 10:51 AM EST - 3 months ago

Organon & Co. (OGN) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 7:30 AM EST - 3 months ago

Organon Reports Results for the Third Quarter Ended September 30, 2025

Nov 7, 2025, 7:30 AM EST - 3 months ago

Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie

Nov 6, 2025, 7:30 AM EST - 3 months ago

Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025

Oct 28, 2025, 2:06 PM EDT - 3 months ago

The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products

Oct 27, 2025, 6:22 PM EDT - 3 months ago

Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper Wholesale Sales Practices, Abrupt CEO Departure -- Hagens Berman

Oct 27, 2025, 7:44 AM EDT - 3 months ago

Organon CEO Kevin Ali to resign after probe into wholesaler sales practices

Oct 27, 2025, 7:30 AM EDT - 3 months ago

Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation

Oct 17, 2025, 7:10 AM EDT - 3 months ago

Organon: Muted H2 2025 Ahead, But Distressed Valuation And Manageable Debt Makes It A Compelling Buy

Sep 19, 2025, 6:00 AM EDT - 4 months ago

European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

Sep 2, 2025, 5:30 AM EDT - 5 months ago

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

Aug 12, 2025, 2:22 PM EDT - 6 months ago

Organon: Valuation Discount Offset By Structural Headwinds

Aug 6, 2025, 11:59 AM EDT - 6 months ago

Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade)

Aug 5, 2025, 1:10 PM EDT - 6 months ago

Organon & Co. (OGN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 7:30 AM EDT - 6 months ago

Organon Reports Results for the Second Quarter Ended June 30, 2025

Jul 22, 2025, 7:30 AM EDT - 7 months ago

Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025

Jul 21, 2025, 4:02 PM EDT - 7 months ago

OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN

Jul 20, 2025, 10:55 AM EDT - 7 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Jul 11, 2025, 9:37 AM EDT - 7 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Jul 10, 2025, 8:18 AM EDT - 7 months ago

OGN COURT NOTICE: Organon & Co. Investors may have been Affected by Fraud – Contact BFA Law by the July 22 Legal Deadline (NYSE:OGN)

Jul 8, 2025, 1:14 PM EDT - 7 months ago

Trade Tracker: Jenny Harrington sells Organon and buys Vici Properties

VICI

Jul 7, 2025, 7:30 AM EDT - 7 months ago

Organon's VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis

Jul 3, 2025, 8:25 AM EDT - 7 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Jul 3, 2025, 1:00 AM EDT - 7 months ago

Karolinska Development receives update from Organon concerning OG-6219

Jul 2, 2025, 8:01 AM EDT - 7 months ago

Organon to halt development of endometriosis pain drug after mid-stage trial failure

Jul 2, 2025, 7:30 AM EDT - 7 months ago

Organon Provides Update on Phase 2 ELENA Proof-of-Concept Study Evaluating OG-6219 in Patients with Endometriosis-Related Pain

Jun 28, 2025, 7:46 AM EDT - 7 months ago

OGN INVESTOR DEADLINE: Organon & Co. Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 22 Court Deadline (NYSE:OGN)

Jun 26, 2025, 9:00 AM EDT - 7 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon Lawsuit - OGN

Jun 23, 2025, 9:00 AM EDT - 8 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon & Co. Lawsuit - OGN

Jun 20, 2025, 9:06 AM EDT - 8 months ago

OGN COURT REMINDER: Organon & Co. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 22 Court Deadline (NYSE:OGN)

johnmchugh Jan. 30 at 4:00 PM

$OGN what is the proposed Sun Pharma purchase price v current debt after Jada disposal?

5 · Reply

BillionerOfKing Jan. 29 at 8:39 PM

0 · Reply

ZacksResearch Jan. 29 at 6:59 PM

0 · Reply

ZacksResearch Jan. 29 at 5:59 PM

0 · Reply

handmedown1 Jan. 27 at 8:22 PM

$OGN i am sure any MMs short are going to try whatever they can to cover lower

0 · Reply

MrNotSoNice Jan. 27 at 5:54 PM

$OGN Long and will add below $7 if it gets there. This stock is stupid cheap and will have its day eventually. 🧐💰📈💊

0 · Reply

PKinUK16 Jan. 25 at 9:31 PM

1 · Reply

c0ffee Jan. 24 at 9:43 PM

0 · Reply

Value1996 Jan. 23 at 3:40 PM

Organon

0 · Reply

BOBJOSCAUWBERGH Jan. 21 at 9:04 PM

$OGN really curious to see if a deal actually gets made. at 14b sale would be around 20/share

0 · Reply

GuruRanger Jan. 21 at 9:00 PM

$OGN maybe this rumor has some legs.

0 · Reply

OptionSamurai Jan. 21 at 4:02 PM

A new candidate for a wheel strategy on our screener: $OGN You can sell a put strike 8.0 (3.9 ATRs away) for 20-Feb-26. Return is 2.6% and 31.0% annualized. ✔ Breakeven is 15.8% away ✔ Dividend yield if assigned is 2.7% ✔ Annualized covered call return is 83.7% 💵 Company has a fundamental score of 9 and a growth score of 5 📈 IV percentile is 62.3% 🔥 See more results & create your own scan here: https://bit.ly/3lR1xIP

0 · Reply

handmedown1 Jan. 20 at 11:57 PM

$OGN

0 · Reply

handmedown1 Jan. 20 at 11:56 PM

$OGN 50$

1 · Reply

handmedown1 Jan. 20 at 11:54 PM

$OGN i think IMO... multiple offers are coming.

0 · Reply

jimpalomba Jan. 20 at 11:41 PM

$OGN

1 · Reply

Newmoves Jan. 20 at 9:00 PM

$OGN what would be the buyout price?

2 · Reply

Tdorsey1776 Jan. 20 at 8:39 PM

$OGN With debt, this may be close to fully valued if the deal is accepted.

2 · Reply

DailyAnalysis Jan. 20 at 7:57 PM

RSI resetting at 50 leaves massive runway. With CCI pushing 86 and Stoch flashing buy, momentum is clearly shifting. $OGN is coiling. The oscillator confluence signals an imminent breakout. @DailyAnalysis

0 · Reply

ZacksResearch Jan. 20 at 5:47 PM

Big FDA win for $OGN — this just upgraded a core product. 🚀 Organon secured FDA approval to extend NEXPLANON use to five years, supported by trials showing no pregnancies and strong efficacy across body weights — a meaningful boost to the product’s value and longevity. See why this approval matters for the stock 👉 https://www.zacks.com/stock/news/2819866/organon-secures-fda-approval-extending-nexplanon-use-to-five-years?cid=sm-stocktwits-2-2819866-teaser-29737&ADID=SYND_STOCKTWITS_TWEET_2_2819866_TEASER_29737

0 · Reply

ZacksResearch Jan. 20 at 4:47 PM

$OGN extends NEXPLANON use to 5 years — game-changer in women’s health? 🌟 The FDA approval introduces a new REMS program, boosting competitive positioning with clinical data showing no pregnancies in years four and five, enhancing patient adherence and reducing costs over time. 📈 See what this means for Organon’s market reach and revenue growth 👉 https://www.zacks.com/stock/news/2819866/organon-secures-fda-approval-extending-nexplanon-use-to-five-years?cid=sm-stocktwits-2-2819866-body-29706&ADID=SYND_STOCKTWITS_TWEET_2_2819866_BODY_29706

0 · Reply

frankster Jan. 20 at 2:43 PM

$OGN it may get bought out but highly doubt at any premium. This was an epic disaster of spin offs from $MRK they absolutely scammed the shareholders and got away with it.

2 · Reply

Market Cap	2.22B
Revenue (ttm)	6.40B
Net Income (ttm)	864.00M
EPS (ttm)	N/A
PE Ratio	2.36
Forward PE	2.37
Profit Margin	13.49%
Debt to Equity Ratio	9.74

Volume	4,568,152
Avg Vol	5,467,324
Day's Range	N/A - N/A
Shares Out	259.98M
Stochastic %K	7%
Beta	0.58
Analysts	Hold
Price Target	$9.93